Life Extension Magazine

Life Extension Magazine June 2004

Natural Prescriptions For Parkinson's Disease

By Bruce Scali

By Bruce Scali

LE Magazine June 2004
Natural Prescriptions For Parkinson's Disease
By Bruce Scali

The Parkinson’s Prescription: Natural Treatments for Multiple Causes

Causative Factor

Diagnostic Test

Medical Treatment Natural Approach

Dopamine loss

P300 brainwave- brain voltage

Levodopa, ropinirole, COMT inhibitors

Tyrosine, vitamin B6, zinc, DHEA, phenylalanine

GABA and serotonin loss

Brain map (QEEG)

Paxil®, Effexor®, other antidepressants

L-theanine, vitamin B12, GABA, inositol, St. John’s
wort, tryptophan

Inorganic toxins/ heavy metals (iron,
manganese, copper)

EDTA challenge, RBC,serum heavy metals
lead, cadmium, (zinc)

D-penicillamine, BAL

IV chelation, zinc, CoQ10

Organic toxins
(MPTP, pesticides,

Pesticide levels, fat biopsy

(None established)

Glutathione, N-acetylcysteine, methionine, cysteine,

Oxidative stress

Homocysteine, vitamin B12, serum vitamin E and C, selenium, beta-carotene

Selegiline, antidepressants (e.g., Zoloft®, glutathione, polyphenols,

Super Alpha Lipoic Acid with Biotin, curcumin, bioflavonoids, tocotrienols


CRP, ESR, TH/TS, interleukin 6 and 8

COX-2 inhibitors (e.g.,Vioxx®, Celebrex®)

NSAIDs (e.g., aspirin,
ibuprofen), green
and black tea, Nexrutine®

Diminished vascular flow, stenosis, cholesterol, mini-strokes

MRI, MRA, PET scan, ultrasound, ABI

Statins (e.g., Zocor®, Lipitor®)

Aspirin, niacin, red
yeast, chelation,
IV HDL, policosanol


DHEA, testosterone, estrogen, progesterone

HGH injections, adrenal hormone, testosterone, estrogen, progesterone

Super MiraForte, HGH secretagogues,

Petrification: calcium in the brain and
blood vessels with amyloid, mini-strokes

Ionized calcium, calcitonin, para-thyroid, progesterone, bone density studies

NMDA antagonists, calcium channel blockers (e.g., Procardia®)

Calcium, boron, strontium, calcitonin, vitamin D

Electrical loss or pause




Metabolic loss

P300 brainwave, PET and SPECT scans

(None established)

CoQ10, creatine,


1. Mohr E, Mendis T, Grimes JD. Late cognitive changes in Parkinson’s disease with an emphasis on dementia. Adv Neurol. 1995;65:97-113.

2. Scali B. Life extension for the brain. Life Extension. March, 2004:46-7.

3. Available at: Accessed March 23, 2004.

4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberg F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci. 1973 Dec;20(4):415-55.

5. Kessler II. Epidemiologic studies of Parkinson’s disease: II. A hospital-based sur- vey. Am J Epidemiol. 1972 Apr;95(4):308-18.

6. Schoenberg BS, Osuntokun BO, Adeuja AOG, et al. Comparison of the prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neur. 1985;35:841-845.

7. Zhang ZX, Roman GC. Worldwide occur- rence of Parkinson’s disease: an updated review. Neuroepidemiology. 1993;12(4):195-208.

8. Betemps EJ, Buncher CR. Birthplace as a risk factor in motor neurone disease and Parkinson’s disease. Int J Epidemiol. 1993 Oct;22(5):898-904.

9. Tan LC, Tanner CM, Chen R, et al. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord. 2003 Jul;18(7):758-63.

10. Duvoisin RC. The genetics of Parkinson’s dis- ease. Adv Neurol. 1993;60:306-15.

11. Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology. 1981 Jan;31(1):77-80.

12. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymor- phism and susceptibility to Parkinson’s dis- ease. Lancet. 1992 Jun 6;339(8806):1375-7.

13. Riley DE. Secondary Parkinsonism, in Parkinson’s Disease and Movement Disorders, Third Edition. Edited by Jankovic J, Tolosa E. New York, LW&W. 1998;317-328.

14. Tröster AI, Fields JA, Koller WC. Parkinson’s disease and Parkinsonism, in Textbook of Geriatric Neuropsychiatry, Second Edition. Edited by Coffey CE, Cummings JL. Washington, D.C., American Psychiatric Press, 2000;562.

15. Tröster AI, Fields JA, Koller WC. Parkinson’s disease and Parkinsonism, in Textbook of Geriatric Neuropsychiatry, Second Edition. Edited by Coffey, CE, Cummings JL. Washington, D.C., American Psychiatric Press, 2000;563.

16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psych. 1992 Mar;55(3):181-4.

17. Olanow CW, Jenner P, Tatton N, Tatton W. Neurodegeneration and Parkinson’s disease, in Parkinson’s Disease and Movement Disorders, Third Edition. Edited by Jankovic J, Tolosa E. New York, LW&W. 1998;67-103.

18. Wolff SP, Garner A, Dean RT. Free radicals, lipids and protein degradation. Trends Biol Sci. 1986;11:27-31.

19. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an x-ray microanalysis. J Neurochem. 1991 Feb;56(2):446-51.

20. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the devel- opment of parkinsonism induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987 Jul;49(1):1-8.

21. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on a-ketoglutarate dehydrogenase com- plex in Parkinson’s disease. Ann Neurol. 1994 Feb;35(2):204-10.

22. Choi DW. Glutamate neurotoxicity and dis- eases of the nervous system. Neuron. 1988 Oct;1(8):623-34.

23. Winkler J, Thal LJ. Clinical potential of growth factors in neurological disorders.CNS Drugs. 1994;2:465-478.

24. Moller JC, Sautter J, Kupsch A. Potential of neurotrophic factors in therapy of Parkinson’s disease. J.Neural Transm. 1996;48:103-112.

25. Parkinson Study Group: Effect of deprenyl- on the progression of disability in early Parkinson’s disease. N Engl J Med. 1989 Nov 16;321(20):1364-71.

26. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurol. 1997 Aug;49(2):393-9.

27. Olanow CW, Koller WC. An algorithm (deci- sion tree) for the management of Parkinson’s disease: treatment guidelines. Neurol. 1998 Mar;50(Suppl 3):S1-S57.

28. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consump- tion preceding Parkinson’s disease: a case- control study. Neurology. 2000 Nov 14;55(9):1350-8.

29. Hellenbrand W, Boeing H, Robra BP, et al. Diet and Parkinson’s disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-fre- quency questionnaire in a case-control study. Neurology. 1996 Sep;47(3):644-50.

30. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antiox- idants in Parkinson’s disease: a population- based, case-control study. Ann Neur. 1996 Jan;39(1):89-94.

31. Tanner CM. Drug-induced movement disor- ders, in Extrapyramidal Disorders in Handbook of Clinical Neurology, Vol 5. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam. Elsevier Science. 1986;185-204.

32. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson’s disease. J Neural Trans Suppl. 1995;45:231-8.

33. Martinez-Martin P, O’Brien CF. Extending levodopa action: COMT inhibition. Neur. 1998 Jun;50 (Suppl 6):S27-S32.

34. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: effi- cacy and safety of long-term treatment. Neurology. 1997 Sep;49(3):665-71.

35. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonism patients with the “wearing off” phenomenon: a double- blind, placebo-controlled, multicenter trial. Neurology. 1997 Oct;49(4):1066-71.

36. Parkinson Study Group. Effectiveness of laz- abemide on the progression of disability in early Parkinson’s disease. Ann Neurol. 1996 Jul;40(1):99-107.

37. Olanow CW. Attempts to obtain neuroprotec- tion in Parkinson’s disease. Neurology. 1997 Jul;49(Suppl 1):S26-S33.

38. Schapira AH, Olanow CW. Neuroprotection in Parkinson’s disease. JAMA. 2004 Jan 21;291(3): 358-64.

39. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci USA. 2003 Apr 29;100(9):5473-8.

40. Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci. 1982 Mar 8;30(10):827-32.

41. Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci. 1990 Jun;52(3-4):225-32.

42. Li H, Klein G, Sun P, Buchan AM. Dehydroepiandrosterone (DHEA) reduces neuronal injury in a rat model of global cere- bral ischemia. Brain Res. 2001 Jan 12;888(2):263-266.

43. Fahn S. An open trial of high-dosage antioxi- dants in early Parkinson’s disease. Am J Clin Nutr. 1991 Jan;53(Suppl 1):S380-S382.

44. Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/cell cyle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem. 2002 Aug 23;277(34):30574-80.

45. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 Nov 1;21(21):8370-77.

46. Braverman ER. The Healing Nutrients Within Third Edition. North Bergen. Basic Health Pub. 2003;118-130.

47. Schulz JB, Henshaw DR, Mathews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995 Apr;132(2):279-83.

48. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann N Y Acad Sci. 2003 Jun;991:120-31.

49. Dzenko KA, Weltzien RB, Pachter JS. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory com- pounds. J Neuroimmunol. 1997 Dec;80(1- 2):6-12.

50. Li RW, David Lin G, Myers SP, Leach DN. Anti-inflammatory activity of Chinese medic- inal vine plants. J Ethnopharmacol. 2003 Mar;85(1):61-7.

51. Mori H, Fuchigami M, Inoue N, Koda A, Nishioka I. Principle of the bark of phel- lodendron amurense to suppress the cellular immune response. Plant Med. 1994 Oct;60(5):445-9.

52. Sandyk R. L-tryptophan in Neuropsychiatric disorders: a review. Int J Neurosci. 1992 Nov- Dec;67(1-4):127-44.

53. Hammerstad J, Hogarth P. Parkinson's dis- ease: surgical options. Curr Neurol Neurosci Rep. 2001 Jul;1(4):313-9.

54. Pollak P, Benabid A-L, Krack P, Limousin P, Benazzouz A. Deep Brain Stimulation in Parkinson’s Disease and Movement Disorders, Third Edition. Edited by Jankovic J, Tolosa E. New York, LW&W. 1998;1085-1101.

55. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body dis- ease. Ann Neur. 1994 Jan;35(1):38-44.

56. Chaturvedi RK, Agrawal AK, Seth K, et al. Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on func- tional restoration in 6-hydroxydopamine (6- OHDA) lesioned rat model of Parkinson’s disease: neurobehavioral, neurochemical and immunohistochemical studies. Int J Dev Neurosci. 2003 Nov;21(7):391-400.

57. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett. 1994 Nov 21;182(1):107-11